An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

Techniques are used for adaptation of drug-administration parameters that control insulin delivery in a blood glucose control system. One technique provides long-term adaptation of a nominal basal infusion rate, adapting to longer-term changes in a patient's needs due to growth, illness, hormonal fluctuations, physical activity, aging, etc. Another technique provides adaptation of priming dose size at mealtimes for overall better glycemic control and also adapting to longer-term changes in a patient's needs. Adaptation calculations use a receding-horizon window of recent values of the adapted parameter. Doses of a counter-regulatory agent (e.g., glucagon) may also be delivered in response to information about estimated accumulation of exogenously infused insulin (subcutaneously, intramuscularly, intraperitoneally, or intravenously) and/or the effect insulin might have on glucose levels (blood glucose concentration or interstitial fluid glucose concentration).

Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.

Embodiments of the present invention provide drug-delivery devices comprising a drug reservoir chamber containing a substance to be delivered, in fluid connection with a drug administration means, and at least one displacement-generating battery cell coupled to said drug reservoir chamber by a coupling means, the at least one displacement-generating battery cell comprising an element that changes shape as a result of discharge of the battery cell so as to cause a displacement within the battery unit, the arrangement being such that the displacement derived from said battery unit is conveyed by said coupling means to cause displacement of at least a portion of a wall of said drug reservoir chamber reducing the volume of said drug reservoir chamber such that said substance is expelled from said drug reservoir chamber towards said drug administration means upon discharge, thereby being a self-powered drug delivery device.

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

Some embodiments a glucagon administration system can provide a suggested glucagon dosage based on one or more particular parameters (e.g., the user's recent blood glucose characteristics, a glucagon sensitivity value of the user, and other parameters). In some circumstances, the glucagon administration system can receive information indicative of the user's blood glucose level and suggest a glucagon dosage that is at least partially dependent upon a previously stored glucagon sensitivity for the user.

Controlled release dosage forms comprising a pharmaceutically active agent capable of not more than 90% release in 12 hours in a simulated gastric juice in first order release rate USP type 1 dissolution test, comprising (a) a tablet made from polymer matrix of at least two biocompatible polymers, the pharmaceutically active agent and excipients; the tablet capable of rapid swelling without disintegration in simulated gastric juice to a size resulting in gastric retention in the stomach and controlled release of the active agent by controlled erosion and diffusion immediately after coming into contact with the gastric juice, or (b) microspheres of ungrafted chitosan or a chitosan derivative or CARBOPOL incorporating the active agent which is not a polymeric molecule and after administration in stomach, the microspheres adhere to the gastric mucosa for a long and controlled time release of the active agent.

The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.

An electronic capsule (100) is provided. The capsule (100) has a discrete drive element (300) comprising: a housing (109), electronics for making the electronic capsule (100) operable, a pumping mechanism (115) for dosing and displacing a substance, a power source (105) for powering the electronic capsule (100) and enabling the electronics and the pumping mechanism (115) to operate, and a locking mechanism (130); and a discrete payload element (200) comprising: a housing (109), a reservoir (210) for storing the substance, one or more openings (250) in the housing (109) for releasing the substance from the reservoir (210) and a locking mechanism (230) for engaging the drive element locking mechanism (130). Engagement of the drive element locking mechanism (130) with the payload element locking mechanism (230) secures the drive element (300) to the payload element (200), thereby making the electronic capsule (100) operable and specific.

A system for the removal of vitreous humor and other fluids from an eye and the reinjection of filtered vitreous humor into the eye is provided. The system comprises a hollow removal device, a filter, and an infusion device. The removal device includes an element configured to cut the vitreous humor and is configured to aspirate the vitreous humor from the eye. The filter is configured to create a filtered form of vitreous humor by separating the vitreous humor from undesired components in the vitreous humor. The infusion device is fluidly coupled to the filter and is configured to return the filtered form of vitreous humor into the eye.